Jonathan Cohen - Selected Publications#


1. Exley AR, Buurman W, Owen R, Hanson G, Lumley J, Aulakh JM, Bodmer M, Riddell A, Stevens S, Perry M, Cohen J. Phase 1 clinical trial of CB0006, a murine monoclonal antibody to recombinant human tumour necrosis factor in patients with severe septic shock. Lancet 1990 335: 1275-1277
This paper described the first-in-man use of a monoclonal anti-TNF.

2. Evans T, Carpenter A, Cohen J. Purification of a distinctive form of endotoxin-induced nitric oxide synthase from rat liver. Proc Natl Acad Sci (USA) 1992 89: 5361-5365
This, and # 5, are evidence of sustained high-level publication of basic science papers in a very competitive field.

3. Evans T, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J. Protective effect of 55- but not 75-kD soluble TNF-receptor-IgG fusion proteins in an animal model of Gram-negative sepsis. J Exp Med 1994 180: 2173-2179.
A highly influential paper; a very unexpected finding because both fusion proteins had been thought to be equivalent and both were being developed for clinical use.

4. Cohen J, Carlet J, for the INTERSEPT Study Group. INTERSEPT: An international multicentre placebo-controlled trial of monoclonal antibody to human TNF-α in patients with sepsis. Crit Care Med 1996 24:1431-1440.
First author on a major, phase III, international, randomised controlled trial.

5. Evans TJ, Buttery LK, Carpenter A, Springall DR, Polak JM, Cohen J. Cytokine-treated human neutrophils contain inducible nitric oxide synthase that produces nitration of ingested bacteria. Proc Natl Acad Sci (USA) 1996 93: 9553-9558.

6. Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen? Proc Natl Acad Sci (USA), 2000 97: 14584-14589.
Reported a previously unknown function for this ubiquitous protein.

7. Cohen J, Immunopathogenesis of sepsis. Nature 2002 420: 885-891
An invited review; evidence of my standing in the field.

8. Dellinger RP, Carlet J, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker, MM, Ramsay G, Zimmerman JL, Vincent J-L, Levy MM. For the Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign management guidelines for management of severe sepsis and septic shock. Crit Care Med 2004 32: 858-873
I was a member of the international guideline committee that published these state-of-the-art recommendations that were adopted worldwide.

9. Rice TW, Wheeler AP, Bernard G R, Vincent J-L, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Li M, Matsuda H, Mouri K, Cohen J. A randomized, double-blind placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010 38(8): 1685 – 1694.
Senior author on an international RCT

10. Cohen J, J-L Vincent, N Adhikari, F Machado, D Angus, T Calandra, K Jaton, S Giuleri, J Delaloye, S Opal, K Tracey, T van der Poll, E Pelfrene. Lancet Infect Dis Commission: Sepsis: a roadmap for future research. Lancet Infect Dis 2015; 15:581-614
I conceived and directed this state-of-the-art publication that has been extremely highly cited.

Imprint Privacy policy « This page (revision-4) was last updated on Friday, 29. September 2017, 10:17 by System
  • operated by